Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.

Vestipitant is a potent and selective neurokinin 1 (NK-1) receptor antagonist that was investigated as a potential treatment for post-operative nausea and vomiting (PONV). A previous mannitol-based formulation of vestipitant was associated with hemolytic activity in preclinical studies. In an effort to reduce the hemolytic potential and develop an IV formulation of vestipitant that could be administered more rapidly, an IV formulation containing sulfobutylether-7-beta-cyclodextrin (SBE7-β-CD, Captisol™) was developed and tested in a phase 1 clinical study.

Polysorbate 80 and Cremophor EL micelles deaggregate and solubilize nystatin at the core-corona interface.

The extent and the location of nystatin solubilization by nonionic surfactant micelles were determined. The critical aggregation concentrations (CAC) of nystatin in 4 x 10(-3) M surfactant were determined by dynamic light scattering. The resulting CAC values for nystatin in Cremophor EL (CrEL), Tween 80 (T80), and Nofable ESO-9920 (NOF) were 150, 150, and 300 microM compared to 10 microM for the phosphate-buffered saline (PBS) control.

The effects of Pluronic block copolymers on the aggregation state of nystatin.

The purpose of this work was to characterize the effect of block copolymer composition on the aggregation state of nystatin in the presence of Pluronic micelles. The critical aggregation concentrations (CACs) of nystatin were determined by dynamic light scattering (DLS). The CAC of nystatin in phosphate-buffered saline was 20 microM at 37 degrees C.